May 22, 2017 09:32 AM EDT
R&D

On a deal spree, Take­da part­ners up with Nek­tar on a slate of can­cer R&D com­bo stud­ies

John Carroll

Editor & Founder

Take­da con­tin­ues its pipeline re­vamp with a new deal to col­lab­o­rate with Nek­tar Ther­a­peu­tics on a slate of new com­bo stud­ies us­ing its lead im­muno …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times